PRESS RELEASE

Link:
Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction

SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors.

Read the original here:
Cidara Therapeutics Announces Key Additions to its Board of Directors

Poster highlights NRP2 expression on immune cells in the tumor microenvironment.

View original post here:
aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression

Thought Leaders Will Advise BrightInsight as Demand Grows for its Regulated Digital Health SaaS Platform Thought Leaders Will Advise BrightInsight as Demand Grows for its Regulated Digital Health SaaS Platform

Link:
BrightInsight Names Technology and Healthcare Leaders to Advisory Council

- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 -

Original post:
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today.

Continue reading here:
Vericel Announces Appointment of Joe Mara as Chief Financial Officer

Innovative Digital Commerce Veteran Joins Dynamic Sales Team Innovative Digital Commerce Veteran Joins Dynamic Sales Team

Follow this link:
Better Choice Company Appoints Jenny Condon as Executive Vice President of Digital Sales

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in the following virtual conferences in February.

More here:
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021

Balance Sheet Strengthened and also Announces Retention of Investor Relations Firm Balance Sheet Strengthened and also Announces Retention of Investor Relations Firm

See the rest here:
Golden Leaf Receives Approval to Extend Maturity of Convertible Debentures

TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has renewed and expanded its distribution agreement for NYDA®, a market leading treatment for head lice, through September 26, 2026. The agreement with G. Pohl-Boskamp GmbH & Co KG ("Pohl-Boskamp") provides the Company with exclusive Canadian distribution rights for NYDA® and includes a commitment related to bringing new and innovative solutions to the Canadian market. The initial agreement with Pohl-Boskamp was signed in 2011 and the first extension was announced in June 2015.

More:
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

Read this article:
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide...

NEW YORK, NY, REHOVAT, ISRAEL, SOUTH KOREA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced a $3.4 million strategic investment (the “Investment”) from tech-focused venture capital firm Yozma Group Korea (“Yozma”).

Original post:
Todos Medical Announces Strategic Investment by Yozma Group Korea

Information regarding the results of mandatory redemption of shares

Original post:
Information regarding the results of mandatory redemption of shares

DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent initiatives and corporate updates.

Visit link:
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead

Excerpt from:
Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version

EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

More:
Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201.  The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.

Read more here:
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

Lille, France; Cambridge, MA; January 25, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced the results of the shareholders’ vote at the Extraordinary Shareholders Meeting which took place on second convening this Monday, January 25, 2021 at 2:30pm (Paris time) (the “Extraordinary Shareholders Meeting”) and the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 (the “OCEANEs”) at the Bondholders Meeting which took place this Monday, January 25 2021 at 5:30pm (the “Bondholders Meeting”.) All resolutions proposed by the Board of Directors at both Meetings were approved with more than 98.5% of votes at the Extraordinary Shareholders Meeting and 100% of votes at the Bondholders Meeting.

Excerpt from:
GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

The rest is here:
Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. The company’s shares will continue to trade under its current symbol “CRMD”. Trading on the Nasdaq Global Market is expected to commence on Tuesday, February 2, 2021. The Company’s shares of common stock will continue to trade on the NYSE American until the close of the market on Monday, February 1, 2021.

Read more:
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange